Related Experiment Video

Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?

David J VanderWeele1, Maha Hussain1

  • 1Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago.

NEJM Evidence
|February 6, 2024
PubMed

Insights

Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show promise in treating metastatic castration-resistant prostate cancer (mCRPC). Combining PARP inhibitors with androgen receptor inhibition may benefit a broader patient group, though results vary across studies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) is a challenging disease.
  • Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are effective in mCRPC with homologous recombination repair (HRR) deficiency.

Discussion:

  • Preclinical data suggest combining PARP inhibitors with androgen receptor inhibition could expand therapeutic benefits.
  • Clinical trials exploring this combination have yielded mixed results.

Key Insights:

  • One Phase 2 trial indicated that olaparib plus abiraterone/prednisone improved radiographic progression-free survival (PFS) in a non-biomarker-selected mCRPC population.
  • Another trial combining abiraterone with veliparib did not demonstrate similar benefits.

Outlook:

  • Further research is needed to clarify the role of PARP inhibitors in combination therapy for mCRPC.
  • Identifying predictive biomarkers may optimize treatment selection for patients with prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K